# Oruka Therapeutics, Inc.: overview ORKA · Nasdaq · CIK 907654 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/orka.md) · [Financials](/companies/orka/financials.md) · [Filings](/companies/orka/filings.md) · [Insiders](/companies/orka/insiders.md) Latest reported revenue: [$0](/filings/0000950170-24-089246.md) for Q2 FY2025, three months to 2024-06-30, from the 10-Q filed Aug 1, 2024 (XBRL us-gaap:Revenues, accession 0000950170-24-089246). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0 d](/filings/0000950170-24-089246.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(6.96)](/filings/0001213900-25-074281.md) | [(1.46)](/filings/0001213900-24-097443.md) | [(0.40)](/filings/0001213900-25-043279.md) | [(0.46)](/filings/0001213900-25-074281.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | not reported | not reported | [(20.9)](/filings/0001213900-26-055769.md) | [(23.2) d](/filings/0001213900-26-087231.md) | [(21.7) d](/filings/0001213900-25-109182.md) | [(22.7) d](/filings/0001213900-26-026929.md) | [(23.7)](/filings/0001213900-26-055769.md) | [(33.1) d](/filings/0001213900-26-087231.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001564590-21-014148.md) | [0.0](/filings/0001564590-22-010075.md) | [0.0](/filings/0000950170-23-004379.md) | [0.0](/filings/0000950170-24-009809.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.07)](/filings/0001564590-22-010075.md) | [(1.39)](/filings/0000950170-23-004379.md) | [(0.69)](/filings/0000950170-24-009809.md) | [(0.37)](/filings/0000950170-24-009809.md) | not reported | | Free cash flow | $m | [(7.7)](/filings/0001564590-22-010075.md) | [(18.8)](/filings/0000950170-23-004379.md) | [(10.9)](/filings/0000950170-24-009809.md) | [(5.0)](/filings/0000950170-24-009809.md) | [(88.4)](/filings/0001213900-26-026929.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/orka/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $862.0m | 9,057,645 | | Added +1,626,242 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $474.9m | 4,990,181 | | Added +1,463,094 | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $394.8m | 4,148,428 | | Unchanged | | [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $352.6m | 3,705,262 | | Unchanged | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $323.7m | 3,401,639 | | New +3,401,639 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $298.7m | 3,139,030 | | Added +1,080,882 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $254.4m | 2,673,090 | | Added +1,059,629 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $224.7m | 2,360,971 | | Added +501,340 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $204.1m | 2,144,526 | | Reduced −175,790 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $183.3m | 1,926,000 | | Reduced −108,203 | ## Recent filings [All 1,062 filings](/companies/orka/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:00 ET | [8-K](/filings/0001213900-26-112281.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-112281 | | 2026-08-24 | 16:06 ET | [8-K](/filings/0001213900-26-093021.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-093021 | | 2026-08-10 | 16:06 ET | [10-Q](/filings/0001213900-26-087231.md) | Quarterly report, period 2026-06-30 | 0001213900-26-087231 | | 2026-08-10 | 07:00 ET | [8-K](/filings/0001213900-26-086933.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-086933 | | 2026-07-01 | 21:30 ET | [SCHEDULE 13D/A](/filings/0001104659-26-080010.md) | Ownership report, active investor, amended | 0001104659-26-080010 | | 2026-06-04 | 16:15 ET | [8-K](/filings/0001213900-26-065294.md) | 5.07 Shareholder vote results | 0001213900-26-065294 | | 2026-06-01 | 16:01 ET | [8-K](/filings/0001213900-26-063481.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-063481 | | 2026-05-13 | 16:01 ET | [10-Q](/filings/0001213900-26-055769.md) | Quarterly report, period 2026-03-31 | 0001213900-26-055769 | | 2026-05-04 | 18:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-055049.md) | Ownership report, active investor, amended | 0001104659-26-055049 | | 2026-04-30 | 16:17 ET | [8-K](/filings/0001213900-26-050249.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-050249 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-026929.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 907654 - Tickers: ORKA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 08:01 ET. No prices; not investment advice.